Printer Friendly

News Briefing, Webcast and Satellite Feed to Announce Medical Discovery; Genetic Screening Recommended to Detect Newly Identified Neurological Disorder In Men Over Age 50.

SACRAMENTO, Calif., Jan. 28 /PRNewswire/ -- A team of researchers, led by physicians at the UC Davis M.I.N.D Institute, have identified a new neurological disorder that predominantly affects men over age 50 and results in tremors, balance problems and memory problems that become increasingly severe with age. The disorder appears later in life in men who are generally healthy throughout childhood and early-to-mid-adulthood, yet is caused by a defect in a gene known to cause mental retardation in future generations.

Researchers began looking for a connection between children and their grandfathers because the mothers of fragile X patients were worried about their own fathers, who were falling down, becoming forgetful and experiencing other neurological problems.

A significant but unknown number of adults with these symptoms are being misdiagnosed with Parkinson's disease, senile dementia and Alzheimer's disease when their condition may be accurately and easily identified with a standard DNA blood test ordered by their doctor.

Nearly 1 in 800 men in the general population carries this premutation in the fragile X gene, and UC Davis research suggests that as many as 30 percent of carriers -- roughly 1 in 3,000 men -- may develop FXTAS later in life.

Screening for the gene mutation in men who have tremor and balance problems is important regardless of their family history, especially when accompanied by other signs such as parkinsonism (rigidity in movement), short-term memory loss and dementia.

A detailed news release with links to graphics, brain images and other press materials are available at . A special telephone line at the UC Davis MIND Institute, 916-703-0200, has been set up to allow patients and physicians who request more information to leave a message. Additional information about Fragile X and FXTAS is also available at the National Fragile X Foundation ( 1-800-688-8765).
 JAN 27th 4:00 pm - 4:15 pm Eastern time / 1:00 pm - 1:15 pm Pacific time
 JAN 28th 1:30 pm - 1:45 pm Eastern time / 10:30 am - 10:45 am Pacific time
 Ku Band analog SBS6 / transponder 4 full (both days)
 Audio: 6.2 & 6.8, downlink frequency: 11798 vertical
 For technical information contact: PACSAT 916-446-7890

CONTACT: Jennifer Conradi, +1-916-734-9064, or pager, +1-916-762-0860 or of U.C. Davis Health System; or UC Davis School of Medicine and Medical Center Public Affairs office, +1-916-734-9040

Web site:

Web site:

Web site:
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 2004
Previous Article:Doubled Revenue Growth and Half-Billion Dollar Savings for Consumers Mark W3 Data Banner Year; Intuitive Searching, Valued Business Products and...
Next Article:2000 Census Shows Big Gains in Public Transit Ridership to Bay Area Downtowns.

Related Articles
Xenon Genetics and RGS Genome Combine To Create World-Leading Clinical Genomics Company.
Boys Town National Research Hospital Launches New Attack On Deafness -- Acquires Breakthrough Genetic Analysis System to Pursue Mutations That Cause...
Wyeth Joins Ingenium's Genetic Rat Model Program.
Children's Memorial, TGen Announce Partnership to Advance High-Tech Genomics Research; Collaboration Will Accelerate Research Into Childhood Diseases.
Ingenium to Provide Merck & Co., Inc. with Genetic Rat Models.
Lexicon extends intellectual property portfolio with patent on gene trapping.
Researchers Identify Gene for a Primary Form of Sudden Infant Death Sydrome (SIDS).
Cleveland Clinic-led research identifies gene linked to epilepsy, movement disorder.
MultiVu Video Feed: New Data Supports a Non-Invasive Approach to Routine Prenatal Genetic Testing.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters